Intellectual Property Manager
Ludwig Institute for Cancer Research
New York, NY
The Ludwig New York Office seeks an Intellectual Property Manager to assist in identifying areas of Ludwig research suitable for patent protection. Working closely with scientists world-wide, members of Ludwig’s Intellectual Property Office and outside patent counsel, the successful candidate will take part in the preparation and prosecution of patent applications. In addition, the IP Manager will work together with the Intellectual Property team in the negotiations and drafting of various agreements, such as license agreements, collaborative research agreements and material transfer agreements (MTAs).
The position would suit candidates looking to transition from a research career to technology transfer and intellectual property commercialization. Applicants should have post-doctoral research experience, preferably at least two years in cancer immunology, epigenetics, metabolism, genomics, or related fields. A wide ranging interest in science and an ability to rapidly assimilate new data are essential. A background in cancer research and some prior experience of technology transfer would be advantageous.
Applicant must be authorized to work in US.
Salary is dependent upon previous experience. Interested candidates should apply in writing by submitting a resumé and two references, before September 16, 2019 to:
Ludwig Institute for Cancer Research Ltd
Attn: Human Resources
666 Third Avenue / 28th Floor
New York, NY 10017
The Ludwig Institute for Cancer Research Ltd is an international not-for-profit organization with a 48-year legacy of pioneering cancer discoveries. The Institute provides its scientists from around the world with the resources and the flexibility to realize the life-changing potential of their work and see their discoveries advance human health. This philosophy, combined with robust translational programs, maximizes the potential of breakthrough discoveries to be more attractive for commercial development.
Since its inception, the Institute has invested more than $1.8 billion of its own resources in cancer research, and has an endowment valued at $1.5 billion.